Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18966864 | 0.84 | KMT2A (0.40) | HRH3RAPGEF4ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL2776485 | 0.82 | SELL (0.46) | HRH3ALDH1A1KDM4ECYP11B1CYP11B2 | |
| SCHEMBL30979268 | 0.82 | SELL (0.46) | HRH3ALDH1A1KDM4ECYP11B1CYP11B2 | |
| SCHEMBL25162110 | 0.82 | ALDH1A1 (0.48) | HRH3RAPGEF4ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL13236569 | 0.82 | TSHR (0.43) | HRH3RAPGEF4ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL23189364 | 0.82 | RAPGEF4 (0.38) | HRH3RAPGEF4ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL13236292 | 0.82 | HRH3 (0.35) | HRH3RAPGEF4ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL18570653 | 0.79 | PTGS2 (0.37) | RAPGEF4HTR1DNOS3NOS2CYP1A2 | |
| SCHEMBL10755095 | 0.78 | ACHE (0.48) | KDM4EMAPT | |
| SCHEMBL29954130 | 0.78 | HRH3 (0.37) | HRH3RAPGEF4ALDH1A1KDM4ECYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119032974-A | Thrips control agent and preparation method thereof | 广西壮族自治区农业科学院 | 2024-11-29 | — | — | CN | claimed |
| EP-0192492-B1 | PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-01-02 | — | — | EP | claimed |
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | BRILLIANT LIGHT POWER, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| CN-119032974-A | Thrips control agent and preparation method thereof | 广西壮族自治区农业科学院 | 2024-11-29 | — | — | CN | disclosed |
| CN-118547298-A | Method for electrochemical reduction of aryl alkene and alkyne | 中国科学院大连化学物理研究所 | 2024-08-27 | — | — | CN | disclosed |
| US-20230045778-A9 | HETEROGENEOUS HYDROGEN-CATALYST SOLID FUEL REACTION MIXTURE AND REACTOR | BRILLIANT LIGHT POWER, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200299130-A1 | HETEROGENEOUS HYDROGEN-CATALYST REACTOR | BRILLIANT LIGHT POWER, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| CN-105916899-B | Optics of liquids adhesive composition | 3M创新有限公司 | 2019-01-18 | — | — | CN | disclosed |
| US-20170101369-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-13 | — | — | US | disclosed |
| CN-104193725-B | Organic compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4677193-A | GONADOTROPIN-RELEASING FACTOR ANALOGS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0192492-A2 | Peptides containing an aliphatic-aromatic ketone side chain | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4596671-A | Organoleptics | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | SCO2, SOD1, HAO2 | HRH3 273/4885RAPGEF4 4452/4885ALDH1A1 3874/4885 |
| US-20170101369-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS | STAT5A, STAT5B, JAK2 | HRH3 2915/4885RAPGEF4 3012/4885ALDH1A1 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.